Search Result Details

This page shows the details of why an item matched the keywords from your search.
One or more keywords matched the following properties of HECZEY, ANDRAS
PropertyValue
keywords adoptive immunotherapy liver cancer neuroblastoma
overview Dr. Andras Heczey is a physician-scientist and full-time faculty in the Department of Pediatrics of Baylor College of Medicine, Section of Pediatric Hematology and Oncology. He is a member of the multidisciplinary solid tumor team and the Center for Cell and Gene Therapy (CAGT). His research focuses on developing novel treatments for children with solid tumors by redirecting the immune system to attack cancer cells. Dr. Heczey has studied and published the first adoptive immunotherapy approach utilizing Natural Killer T cells genetically modified to attack neuroblastoma, he is working on moving this approach from bench-to-bedside in a form of a Phase 1/2a clinical trial. As the Director of the Liver Tumor Program of Texas Children's Hospital, Dr. Heczey has developed a strategy to target hepatoblastoma and hepatocellular carcinoma with genetically engineered T lymphocytes and he is currently evaluating this strategy in early Phase clinical trials in children and adults. Dr. Heczey is a member of the Liver Tumor Program, the Neuroblastoma Program, the Solid Tumor Team and the Center for Advanced Innate Cell Therapy.
One or more keywords matched the following items that are connected to HECZEY, ANDRAS
Item TypeName
Academic Article IL-15 protects NKT cells from inhibition by tumor-associated macrophages and enhances antimetastatic activity.
Concept Neuroblastoma
Academic Article Advances in chimeric antigen receptor immunotherapy for neuroblastoma.
Academic Article Invariant NKT cells with chimeric antigen receptor provide a novel platform for safe and effective cancer immunotherapy.
Academic Article IMAGES IN CLINICAL MEDICINE. Osteopetrosis and Erlenmeyer-Flask Deformity.
Academic Article CD62L+ NKT cells have prolonged persistence and antitumor activity in vivo.
Academic Article CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma.
Academic Article Therapy-related Acute Leukemia With Mixed Phenotype and Novel t(1: 6)(q25;p23) After Treatment for High-risk Neuroblastoma.
Academic Article 50 Years Ago in The Journal of Pediatrics: Survival of Children with Neuroblastoma Treated with Combination Chemotherapy.
Academic Article NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In Vivo Persistence and Antitumor Activity against Neuroblastoma.
Academic Article Is high-risk neuroblastoma induction chemotherapy possible without G-CSF? A pilot study of safety and treatment delays in the absence of primary prophylactic hematopoietic growth factors.
Academic Article Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis.
Academic Article Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Academic Article GD2-CAR CAR T?cells in patients with osteosarcoma and neuroblastoma-it's not only the T cells that matter.
Academic Article Author Correction: Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results.
Search Criteria
  • neuroblastoma